Competition, Government, Healthcare Provider and Pharmaceutical products

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Competition

Government

Healthcare Provider

Pharmaceutical products

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

SEPTEMBER 29, 2022

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme. About the auth or.

Management

Management Food and Drug Administration Manufacturing Pharmaceutical manufacturing

Uri Goren

Cadensee

JULY 20, 2021

But there's a lot of other things that bother patients and might be a target for healthcare technology, or pharmaceutical products. But in terms of Israel as a competitive advantage, I think data is much more than just good technology. It doesn't have to have patients inside it. It's a different part of it.

Food and Drug Administration

Food and Drug Administration Doctors Healthcare Healthcare

Pharma Rep Focus

Economics and risks of FDA’s Quality management maturity rating programme

Uri Goren

Stay Connected